drugset / Trial / NCT00702754
Open Label Safety/Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) in Patients With Cervical Dystonia
NaSingle-groupOpen-labelTreatment
Summary
Open label study to evaluate the safety and immunogenicity of MYOBLOC (Botulinum Toxin Type B) in adult patients with a clinical diagnosis of Cervical Dystonia (CD).
Timeline
- Start
- 2001-06
- Primary completion
- 2008-05
- Completion
- 2008-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Botulinum Toxin Type B | Unknown | 5000 iu | — |
| Subject | Botulinum Toxin Type B | Unknown | 25000 iu | — |